Composition for inhibiting oil secretion, preparation method and application thereof

Abstract

The present invention relates to the field of cosmetic technology, and in particular, to a composition for inhibiting oil secretion, a preparation method thereof, and an application thereof. The composition for inhibiting oil secretion of the present invention comprises, by weight, 0.5 to 3 parts of puerarin and 0.1 to 2 parts of coumestrol. The present invention can inhibit oil secretion through the coordinated action of puerarin and coumestrol, and has a significant oil control effect.

Description

Technical Field

[0001] The present invention relates to the technical field of cosmetics, and in particular to a composition for inhibiting oil secretion, a preparation method and application thereof. Background Art

[0002] Excessive secretion of sebaceous glands is a problem for oily and combination skin, and oily face is a problem for many women who love beauty. Many oil control products in the prior art are acidic, and long-term use will damage the skin barrier and cause sensitive skin. Therefore, plant ingredients from natural sources have unique advantages.

[0003] Puerarin, also known as 8-β-D-glucose pyranose-4',7-dihydroxyisoflavone, is distributed in leguminous plants. Its chemical structure is similar to estradiol, so it has estrogen-like effects and is one of the common isoflavone phytoestrogens; the chemical structure of puerarin is as follows:

[0004]

[0005] In addition, puerarin can regulate the cell cycle and inhibit PTK activity; it can also inhibit insulin-stimulated glucose uptake and reduce ATP in adipocytes, and inhibit insulin-induced lipolysis in isolated rat adipocytes. Studies have shown that puerarin can prevent and treat cancer by inhibiting the activation of p38MAPK in the mitogen-activated protein kinase (MAPK) pathway and reducing the synthesis of inhibitory protein α in the redox-sensitive transcription factor NF-κB pathway. In addition, many metabolic diseases including diabetes and obesity are often treated with puerarin.

[0006] Coumestrol, also known as pseudoestrol and coumestrol, is a coumarin derivative. It was originally extracted from white clover and has estrogenic activity, but unlike most existing isoflavone phytoestrogens, coumestrol belongs to benzofuranocoumarin. It is mainly found in some leguminous fodder plants such as clover, radix scutellariae and soybeans, and in traditional Chinese medicines such as qinpi, peucedanum, angelica dahurica, cnidium monnieri and psoralea corylifolia. It is most abundant in clover and alfalfa sprouts. As a type of phytoestrogen, it has both estrogenic and anti-estrogenic effects. Compared with other phytoestrogens, the distribution range and content of coumestrol are much smaller, but its biological efficacy is twice that of genistein. The chemical structure of coumestrol is as follows:

[0007]

[0008] Current studies have confirmed that phytoestrogens such as coumestrol have a good regulatory effect on female menopausal syndrome, cardiovascular disease, cancer, osteoporosis and reproductive system, and some of these functions have also been confirmed in coumestrol.

[0009] In view of this, the present invention is proposed. Summary of the invention

[0010] One object of the present invention is to provide a composition for inhibiting oil secretion, which can inhibit oil secretion through the coordinated action of puerarin and coumestrol, and has a significant oil control effect.

[0011] Another object of the present invention is to provide a method for preparing the composition for inhibiting oil secretion, which is simple and easy to implement, and the obtained composition has a good oil control effect.

[0012] Another object of the present invention is to provide an application of the composition for inhibiting oil secretion in the preparation of cosmetics.

[0013] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0014] A composition for inhibiting oil secretion comprises 0.5-3 parts of puerarin and 0.1-2 parts of coumestrol, calculated by weight.

[0015] In one embodiment, the composition for inhibiting oil secretion comprises 1.5 to 3 parts of puerarin and 0.5 to 1 part of coumestrol, by weight.

[0016] In one embodiment, the composition for inhibiting oil secretion includes 2 parts of puerarin and 0.5 parts of coumestrol, by weight.

[0017] In one embodiment, the dosage form of the composition includes at least one of a liquid dosage form and an ointment.

[0018] In one embodiment, the composition further comprises an auxiliary material; the auxiliary material comprises a solvent.

[0019] In one embodiment, in the composition, the total mass fraction of puerarin and coumestrol is 1% to 15%.

[0020] In one embodiment, the auxiliary material further includes a functional auxiliary agent; the functional auxiliary agent includes at least one of an emulsifier, a solubilizer, an antioxidant and a fragrance.

[0021] In one embodiment, in the composition, the mass fraction of the functional additive is 0.1% to 5%.

[0022] The method for preparing the composition for inhibiting oil secretion comprises the following steps:

[0023] The mixture of puerarin, coumestrol and auxiliary materials is heat-treated to obtain a composition for inhibiting oil secretion.

[0024] In one embodiment, the heat treatment specifically includes: heating the mixture of puerarin, coumestrol and excipients to 70-85°C, stirring at 70-85°C for 20-35 minutes, cooling to 35-45°C, and keeping warm at 35-45°C for 50-70 minutes.

[0025] Application of the composition for inhibiting oil secretion in the preparation of cosmetics.

[0026] In one embodiment, the cosmetic comprises at least one of a cleanser, a cream, a toner, an essence and a cream.

[0027] Compared with the prior art, the present invention has the following beneficial effects:

[0028] (1) The composition of the present invention can inhibit oil secretion through the coordinated combination of puerarin and coumestrol, and has a significant oil control effect.

[0029] (2) The present invention heat-treats the mixture of the components to obtain a composition for inhibiting oil secretion having an excellent oil control effect.

[0030] (3) The composition of the present invention is applied to cosmetics to improve the oil control effect of the cosmetics. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0032] Figure 1 The graph is a dose-effect curve of the composition for inhibiting oil secretion of Example 1 of the present invention and the diluted composition thereof on the inhibition of 5α-reductase;

[0033] Figure 2 The graph is a dose-effect curve of the composition for inhibiting oil secretion of Example 2 of the present invention and the diluted composition thereof on the inhibition of 5α-reductase;

[0034] Figure 3The graph is a dose-effect curve of the composition for inhibiting oil secretion of Example 3 of the present invention and the diluted composition thereof on the inhibition of 5α-reductase;

[0035] Figure 4 The graph is a dose-effect curve of the inhibitory effect of puerarin solution of different concentrations on 5α-reductase;

[0036] Figure 5 This is the dose-effect curve of the inhibitory effect of coumestrol solution with different concentrations on 5α-reductase;

[0037] Figure 6 This is a dose-effect curve of the inhibitory effect of finasteride solutions of different concentrations on 5α-reductase. DETAILED DESCRIPTION

[0038] The embodiments of the present invention will be described in detail below in conjunction with the examples, but it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. If no specific conditions are specified in the examples, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.

[0039] According to one aspect of the present invention, the present invention relates to a composition for inhibiting oil secretion, which comprises 0.5 to 3 parts of puerarin and 0.1 to 2 parts of coumestrol, calculated by weight.

[0040] The present invention combines puerarin and coumestrol to obtain a composition for inhibiting oil secretion. The coordinated combination of puerarin and coumestrol can have a significant oil control effect.

[0041] In one embodiment, in parts by mass, puerarin is 0.5, 0.8, 1, 1.5, 1.8, 1, 9, 2, 2.1, 2.2, 2.5, 2.8 or 3 parts; coumestrol is 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.5, 1.8, 1.9 or 2 parts.

[0042] In one embodiment, the composition for inhibiting oil secretion comprises 1.5 to 3 parts of puerarin and 0.5 to 1 part of coumestrol, by weight.

[0043] In one embodiment, the composition for inhibiting oil secretion includes 2 parts of puerarin and 0.5 parts of coumestrol, by weight.

[0044] In one embodiment, in the composition for inhibiting oil secretion of the present invention, the mass ratio of puerarin to coumestrol is 1.5 to 5. In one embodiment, in the composition for inhibiting oil secretion of the present invention, the mass ratio of puerarin to coumestrol is 1.5, 2, 2.5, 3, 3.2, 3.5, 3.6, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5 or 5, etc. Further, in the composition for inhibiting oil secretion of the present invention, the mass ratio of puerarin to coumestrol is 3 to 4.5. The mass ratio of puerarin to coumestrol of the present invention is within a specific range, so that the composition for inhibiting oil secretion has a better oil control effect. Further, in the composition for inhibiting oil secretion of the present invention, the mass ratio of puerarin to coumestrol is preferably 4.

[0045] In one embodiment, the dosage form of the composition includes at least one of a liquid dosage form and an ointment. In the present invention, the dosage form of the composition includes but is not limited to a liquid dosage form and an ointment, and auxiliary materials can be added according to actual preparation needs to obtain a composition of a desired dosage form.

[0046] In one embodiment, the administration of the composition of the present invention comprises topical administration.

[0047] In one embodiment, the composition further comprises an auxiliary material; the auxiliary material comprises a solvent.

[0048] In one embodiment, the solvent includes at least one of butylene glycol, glycerol, and propylene glycol.

[0049] In one embodiment, in the composition, the total mass fraction of puerarin and coumestrol is 1% to 15%, for example, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13% or 15%, etc.

[0050] In one embodiment, the auxiliary material further includes a functional auxiliary agent; the functional auxiliary agent includes at least one of an emulsifier, an antioxidant and a fragrance.

[0051] In one embodiment, the emulsifier includes at least one of hydrogenated lecithin, sorbitan olivate, polyglyceryl-3 cocoate, cetearyl alcohol, and polysorbate-80.

[0052] In one embodiment, the antioxidant includes at least one of resveratrol, glycyrrhizin, p-hydroxyacetophenone, tocopherol, astaxanthin and tea polyphenols.

[0053] In one embodiment, the fragrance includes essence, such as floral essence, including at least one of the fragrances of rose, jasmine, magnolia, clove, gardenia, lavender, fragrant bamboo stone, osmanthus, violet, chrysanthemum and ylang-ylang.

[0054] In one embodiment, in the composition, the mass fraction of the functional additive is 0.1% to 5%, for example, 0.1%, 0.5%, 1%, 2%, 3%, 4% or 5%.

[0055] According to another aspect of the present invention, the present invention also relates to a method for preparing a composition for inhibiting oil secretion, comprising the following steps:

[0056] The mixture of puerarin, coumestrol and auxiliary materials is heat-treated to obtain a composition for inhibiting oil secretion.

[0057] The composition with good oil control effect is obtained by heat-treating the mixture of various raw material components.

[0058] In one embodiment, the heat treatment specifically includes: stirring and heating the mixture of puerarin, coumestrol and excipients to 70-85°C (e.g., 70°C, 72°C, 75°C, 78°C, 79°C, °80C, etc.), stirring and treating at 70-85°C for 20-35min (e.g., 20min, 25min, 30min, 35min, etc.), cooling to 35-45°C (e.g., 35°C, 38°C, 40°C, 45°C, etc.), keeping warm at 35-45°C for 50-70min (e.g., 50min, 55min, 60min, 65min, 70min, etc.), and a constant temperature water bath can be used for the above-mentioned heat preservation. The above-mentioned heat treatment conditions of the present invention can further promote the synergistic effect of puerarin and coumestrol, so that the obtained composition has a more significant oil control effect.

[0059] According to another aspect of the present invention, the present invention also relates to the use of the composition for inhibiting oil secretion in the preparation of cosmetics.

[0060] The composition for inhibiting oil secretion of the present invention can be used to prepare cosmetics, and can play an excellent role in regulating the secretion of sebaceous glands, thereby achieving a significant oil control effect.

[0061] In one embodiment, the cosmetic comprises at least one of a cleanser, a cream, a toner, an essence and a cream.

[0062] The following is further explained in conjunction with specific embodiments.

[0063] Example 1

[0064] The composition for inhibiting oil secretion comprises, by weight, 3 parts of puerarin, 1 part of coumestrol and 26 parts of butanediol.

[0065] The preparation method of the composition for inhibiting oil secretion of this embodiment comprises: mixing the components uniformly according to the above proportions, then stirring and heating to 80° C., stirring at 80° C. for 30 minutes, cooling to 40° C., and keeping in a constant temperature water bath for 1 hour to obtain the composition for inhibiting oil secretion.

[0066] Example 2

[0067] The composition for inhibiting oil secretion comprises, by weight, 0.5 parts of puerarin, 0.1 parts of coumestrol and 29.4 parts of butanediol.

[0068] The preparation method of the composition for inhibiting oil secretion of this embodiment is the same as that of Example 1 except that the proportion of the components is different.

[0069] Example 3

[0070] The composition for inhibiting oil secretion comprises, by weight, 2 parts of puerarin, 0.5 parts of coumestrol and 27.5 parts of butanediol.

[0071] The preparation method of the composition for inhibiting oil secretion is the same as that of Example 1 except that the proportions of the components are different.

[0072] Example 4

[0073] The composition for inhibiting oil secretion comprises, by weight, 2 parts of puerarin, 0.5 parts of coumestrol and 27.5 parts of butanediol.

[0074] The preparation method of the composition for inhibiting oil secretion of this embodiment comprises: mixing the components uniformly, heating to 70° C. with stirring, stirring at 70° C. for 35 minutes, cooling to 35° C., and keeping in a constant temperature water bath for 70 minutes to obtain the composition for inhibiting oil secretion.

[0075] Example 5

[0076] The composition for inhibiting oil secretion comprises, by weight, 2 parts of puerarin, 0.5 parts of coumestrol and 27.5 parts of butanediol.

[0077] The preparation method of the composition for inhibiting oil secretion in this embodiment comprises: mixing the components uniformly, heating to 85° C. with stirring, stirring at 85° C. for 20 minutes, cooling to 45° C., and keeping in a constant temperature water bath for 50 minutes to obtain the composition for inhibiting oil secretion.

[0078] Experimental example

[0079] 1. 5α-reductase inhibition test

[0080] Preparation of drugs to be tested

[0081] Composition group for inhibiting oil secretion: The present invention dilutes the composition sample for inhibiting oil secretion of Example 1 to obtain samples of 8 concentrations: the composition of Example 1 (named as component combination A in Table 2) and other 7 compositions of different concentrations. Preparation of other 7 compositions of different concentrations: Taking the concentration of the composition for inhibiting oil secretion in Example 1 as the initial concentration, 7 2-fold gradient dilutions were made using 50% butanediol to obtain 7 groups of compositions for inhibiting oil secretion of different concentrations, as shown in Table 2 below. In Table 2, the concentration of 1.000 mL / mL corresponds to Example 1. The composition for inhibiting oil secretion of Example 2 (named as component combination B in Table 3) and the composition for inhibiting oil secretion of Example 3 (named as component combination C in Table 3) were diluted according to the gradient dilution method of Example 1 above to obtain 8 composition samples of different concentrations, as shown in Table 3 below.

[0082] The control group was as follows:

[0083] Puerarin solution group: The puerarin sample was prepared according to the same amount of the total mass of puerarin and coumestrol as in Example 1, and then diluted according to the above method to prepare 8 puerarin solutions of different concentrations. The concentrations of the 8 puerarin solutions were 1.000 mL / mL, 0.500 mL / mL, 0.250 mL / mL, 0.125 mL / mL, 0.063 mL / mL, 0.031 mL / mL, 0.016 mL / mL, and 0.008 mL / mL, respectively, as shown in Table 4 below.

[0084] Coumestrol solution group: The coumestrol sample was prepared according to the same amount of the total mass of puerarin and coumestrol as in Example 1, and then diluted to prepare 8 coumestrol solutions of different concentrations. The concentrations of the 8 coumestrol solutions were 1.000 mL / mL, 0.500 mL / mL, 0.250 mL / mL, 0.125 mL / mL, 0.063 mL / mL, 0.031 mL / mL, 0.016 mL / mL, and 0.008 mL / mL, respectively, as shown in Table 4 below.

[0085] Finasteride solution group: The positive control finasteride was diluted 2-fold using anhydrous ethanol to prepare 5 finasteride solutions of different concentrations, namely 0.05 μg / mL, 0.025 μg / mL, 0.0125 μg / mL, 0.00625 μg / mL, and 0.003125 μg / mL, as shown in Table 2 below.

[0086] Specific experimental methods include:

[0087] Mouse liver was dissected and homogenized by adding Tris buffer at a ratio of 1:5 at 0℃, centrifuged at 4℃ and 10000g for 15 minutes, and the supernatant was centrifuged at 0℃ and 55000g for 1 hour and then taken out and placed at 4℃ for later use. The reagents and samples in the reaction system in Table 1 were added to the above supernatant. Different dilution samples of different drugs to be tested and finasteride were added 4 times. After incubation at 37℃ for 60 minutes, the decrease in absorbance at 340nm was measured.

[0088] The inhibition rate expression is:

[0089] The amounts of reagents used in the reaction system are shown in Table 1.

[0090] Table 1 Reagent dosage of reaction system

[0091]

[0092] The composition for inhibiting oil secretion in Example 1 (ingredient combination A) and the diluted composition thereof and the inhibition rate and IC of 5α-reductase by finasteride 50 The test results are shown in Table 2. The inhibitory effect curve of the composition for inhibiting oil secretion of the present invention (ingredient combination A) on 5α-reductase is shown in Table 2. Figure 1 As shown, the curve equation is: y = -107.26x 2 +178.57x+15.832, R2=0.9835, y represents inhibition rate, x represents concentration, and R represents correlation coefficient. The inhibitory effect curve of finasteride on 5α-reductase is shown in the figure below: Figure 6 As shown, the curve equation is: y = -13357x 2 +1869.3x+2.6934, R2=0.9917, y represents inhibition rate, x represents concentration, and R represents correlation coefficient.

[0093] Table 2 Compositions for inhibiting oil secretion and inhibition rate and IC of 5α-reductase by finasteride 50

[0094]

[0095]

[0096] The inhibitory effects of the composition for inhibiting oil secretion of Example 2 of the present invention (ingredient combination B) and the composition for inhibiting oil secretion of Example 3 (ingredient combination C) on 5α-reductase are shown in Table 3. The inhibitory effect curve of the composition for inhibiting oil secretion of the present invention (ingredient combination B) and the diluted composition on 5α-reductase is shown in Table 3. Figure 2 As shown, Figure 2The curve equation is: y = 0.0816ln (x) + 0.5478, wherein y represents the inhibition rate and x represents the concentration. The inhibitory effect curve of the composition for inhibiting oil secretion of the present invention (ingredient combination c) and the diluted composition on 5α-reductase is shown in the figure Figure 3 As shown, Figure 3 The equation of the curve in: y = -1.1754x 2 +2.7578x+0.1027, y represents the inhibition rate, and x represents the concentration.

[0097] Table 3 Inhibitory effects of component combination B and component combination C on 5α-reductase

[0098]

[0099] The inhibition rate and IC of 5α-reductase by puerarin and coumarin in the control group were 50 As shown in Table 4. The dose-effect curve of puerarin's inhibitory effect on 5α-reductase is shown in Figure 4 As shown, Figure 4 The curve equation is: y = 0.0641ln (x) + 0.2571, y represents the inhibition rate, x represents the concentration. The dose-effect curve of coumestrol on 5α-reductase is as follows Figure 5 As shown, Figure 5 The curve equation is: y=0.0286ln(x)+0.2852, y represents inhibition rate, and x represents concentration.

[0100] Table 4 Inhibition rate and IC of 5α-reductase by puerarin and coumarin 50

[0101]

[0102] As shown in Table 2 and Table 3, the composition for inhibiting oil secretion of the present invention and the positive control finasteride both have an inhibitory effect on the activity of 5α-reductase. The IC 50 The IC value of the composition for inhibiting oil secretion (ingredient combination A) in Example 1 of the present invention is 0.033 μg / mL. 50 The IC50 of the composition for inhibiting oil secretion in Example 2 (ingredient combination B) is 0.537 mL / mL, and the IC50 of the composition for inhibiting oil secretion in Example 1 (ingredient combination C) is 0.142 mL / mL. The composition for inhibiting oil secretion in the present invention has a high inhibition rate on 5α-reductase within an appropriate concentration range.

[0103] As shown in Table 4, puerarin and coumestrol did not show obvious dose-effect relationship. The inhibition rate of 5α-reductase activity by puerarin or coumestrol alone was significantly lower than that of the composition for inhibiting oil secretion of the present invention.

[0104] 2. Golden Hamster Sebaceous Gland Spot Test

[0105] After 10 days of adaptive feeding, 50 golden hamsters were randomly divided into 5 groups, each with 10 hamsters, including a control group, a blank matrix group, a puerarin group, a coumestrol group, and a composition group for inhibiting oil secretion in embodiments 1 to 3 of the present invention. Before the experiment, the hamsters were shaved with a pet clipper to fully expose the sebaceous gland spots on both sides of the back, and the size of the sebaceous gland spots was measured. The control group was not given medication, and the golden hamsters in the medication group were smeared with drugs on their sebaceous gland spots, once a day, and 0.2 mL was applied to each sebaceous gland spot each time, and the medication was given for 28 days in total, wherein the sebaceous gland spot area was detected once on the 0th, 7th, 14th, 21st, and 28th days, and the hamsters were fasted but not watered before the detection on the 28th day, and were killed after the detection, the sebaceous gland spots were cut off, and 4% paraformaldehyde was used for tissue fixation.

[0106] The test results are shown in Table 5.

[0107] Table 5 Test results of sebaceous gland spot area of ​​each group of golden hamsters

[0108]

[0109] Note: *: compared with the control group, P < 0.05; #: compared with the blank matrix group, P < 0.05.

[0110] As shown in Table 5, there was no significant difference in the area of ​​sebaceous gland spots of golden hamsters in each group before medication (P>0.05); after the 14th day, there was a significant difference between the combination group inhibiting oil secretion and the control group and the blank matrix group (P<0.05); on the 28th day, there were significant differences between the coumestrol group and the combination group inhibiting oil secretion and the control group (P<0.05), and there was also a significant difference between the combination group inhibiting oil secretion and the blank matrix group (P<0.05); and the oil control ability of the combination of ingredients at different proportions was also different, among which the composition of Example 3 had the best oil control effect; in addition, the mean value of the puerarin group was lower than that of the control group and the blank matrix group, but there was no significant difference (P>0.05).

[0111] From the above, it can be seen that the composition for inhibiting oil secretion of the present invention has a better oil control effect than puerarin alone or coumestrol alone, that is, the two have an excellent synergistic effect at an appropriate ratio.

[0112] 3. SZ95 cell assay

[0113] Cell culture: Complete medium is Sebomed basal medium supplemented with 10% calf serum, 20 ng / mL epidermal growth factor (EGF), 100 U / mL penicillin, and 200 μg / mL streptomycin. SZ5 cells are cultured in an incubator at 37°C and 5% CO2 in a saturated humidity, and the culture medium is replaced every 2 days.

[0114] Experimental steps include:

[0115] 1) SZ95 cells in the logarithmic growth phase were inoculated into a 6-well plate, with a cell count of 2*10 5 / well, add 2 mL of culture medium to each well, and add drugs. Set up 3 parallel wells for each drug concentration, and use 2% DMSO culture medium without drugs as a blank control, and mark it well;

[0116] 2) After culturing at 37°C and 5% CO2 for 48 hours, the cells were washed twice with PBS and different concentrations of culture medium containing samples were added;

[0117] 3) After 48 hours of continuous culture, the cells were washed twice with PBS and digested with 0.25% trypsin containing 0.02% EDTA for 5 minutes (the time can be appropriately extended to allow all cells to be digested);

[0118] 4) Add 0.5 mL of culture medium containing 10% calf serum to terminate digestion, and aspirate the culture medium containing cells into a 1.5 mL eppendorf tube;

[0119] 5) Centrifuge at 800-1000 rpm for 5 minutes, carefully discard the supernatant, add 1 mL of PBS, and gently pipette to wash the cells;

[0120] 6) Repeat step 5 and discard the supernatant;

[0121] 7) Add 990 μL of PBS and gently blow the cells with the tip of a pipette to prepare a single-cell suspension (in PBS);

[0122] 8) Add 10 μL of Nile Red fluorescent storage dye solution to each tube to a final concentration of 100 ng / mL, incubate at room temperature for 30 minutes, vortex briefly, and filter through a 300-mesh nylon filter into a test tube for flow cytometry;

[0123] 9) The average fluorescence intensity of each cell in 10,000 cells of each marker was measured on a flow cytometer; the wavelength was 485 nm for excitation and 565 nm for emission.

[0124] The groups formed by different drugs include: a control group; a blank matrix group; a coumestrol group; a puerarin group; and the lipid secretion inhibiting composition groups of Examples 1 to 3 (Example 1 Group, Example 2 Group, Example 3 Group).

[0125] Specific experimental steps include:

[0126] Experimental steps:

[0127] The effects of each group on lipid synthesis in SZ95 cells are shown in Table 5.

[0128] Table 5 Effects on lipid synthesis in SZ95 cells (fluorescence units, n=3)

[0129]

[0130]

[0131] Note: *: compared with the control group, P < 0.05; #: compared with the blank matrix group, P < 0.05.

[0132] As shown in Table 5, after 48 hours of action, the composition for inhibiting oil secretion of Example 3 decreased the fluorescence intensity of Nile red stained cells by 28.03% (P < 0.05), the composition for inhibiting oil secretion of Example 1 decreased the fluorescence intensity of Nile red stained cells by 22.45%, the composition for inhibiting oil secretion of Example 2 decreased the fluorescence intensity of Nile red stained cells by 15.03%, and the coumestrol group decreased by 11.30% (P < 0.05); the puerarin group and the blank matrix group also decreased, but there was no significant difference (P > 0.05). The composition for inhibiting oil secretion of the present invention shows a significant effect of inhibiting lipid production.

[0133] From the above, it can be seen that the composition obtained by coumestrol and puerarin in the present invention can effectively inhibit sebaceous gland secretion and improve the oil control effect. Among them, the composition for inhibiting oil secretion formed by the mass ratio of puerarin to coumestrol of 4:1 has a better effect.

[0134] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A composition for inhibiting oil secretion, characterized in that: Calculated by weight, it consists of 0.5-3 parts of puerarin and 0.1-2 parts of coumestrol.

2. The composition for inhibiting oil secretion according to claim 1, characterized in that: Calculated by weight, it consists of 1.5-3 parts of puerarin and 0.5-1 part of coumestrol.

3. The composition for inhibiting oil secretion according to claim 2, characterized in that: Calculated by weight, it consists of 2 parts of puerarin and 0.5 parts of coumestrol.

4. The composition for inhibiting oil secretion according to claim 1, characterized in that: The dosage form of the composition includes at least one of a liquid dosage form and an ointment.

5. The composition for inhibiting oil secretion according to claim 1, characterized in that: The composition further comprises an auxiliary material; the auxiliary material is a solvent.

6. The composition for inhibiting oil secretion according to claim 5, characterized in that: In the composition, the total mass fraction of puerarin and coumestrol is 1% to 15%.

7. The composition for inhibiting oil secretion according to claim 5, characterized in that: The auxiliary materials also contain functional additives; The functional auxiliary agent includes at least one of an emulsifier, a solubilizer, an antioxidant and a fragrance.

8. The composition for inhibiting oil secretion according to claim 7, characterized in that: In the composition, the mass fraction of the functional additive is 0.1% to 5%.

9. The method for preparing a composition for inhibiting oil secretion according to any one of claims 1 to 8, characterized in that: The following steps are involved: The mixture of puerarin, coumestrol and auxiliary materials is heat-treated to obtain a composition for inhibiting oil secretion.

10. The method for preparing the composition for inhibiting oil secretion according to claim 9, characterized in that: The heat treatment specifically includes: heating the mixture of puerarin, coumestrol and auxiliary materials to 70-85° C., stirring at 70-85° C. for 20-35 min, cooling to 35-45° C., and keeping warm at 35-45° C. for 50-70 min.

11. Use of the composition for inhibiting oil secretion according to any one of claims 1 to 8 in preparing cosmetics for regulating sebaceous gland secretion.

12. The use according to claim 11, characterized in that: The cosmetics include at least one of cleansing milk, cream, toner, essence and cream.

Images